Navigation Links
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Date:1/22/2014

A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert MTB/RIF includes new studies published since the original Cochrane Review was published in January last year. Led by Karen Steingart, an Editor with the Cochrane Infectious Diseases Group at LSTM, the researchers found that Xpert MTB/RIF is more accurate than smear microscopy for diagnosing TB and also accurate for detecting rifampicin resistance. This updated Cochrane Review was one of three WHO reviews commissioned as part of the process to update the policy on the use of Xpert MTB/RIF. The WHO policy is available at http://www.stoptb.org/wg/gli/xpert.asp.

TB causes tremendous suffering worldwide, especially in low- and middle-income countries. Around 8.6 million people developed the disease for the first time in 2012 and 1.3 million people died. TB can be cured if the disease is diagnosed and properly treated. Being able to detect TB and TB drug resistance is vital for improving health, reducing deaths and decreasing the spread of TB.

Xpert MTB/RIF is a new test that quickly detects TB and resistance to rifampicin, one of the major drugs for treating the disease. Xpert MTB/RIF is automated and can detect TB bacteria at low concentrations. In addition, the test does not require expert staff or an advanced laboratory. In contrast, smear microscopy, the most frequently used test for TB detection in resource-constrained settings requires TB bacteria to be present at high concentrations (thousands of bacteria) and does not diagnose drug resistance. Instead TB would have to be grown in a laboratory, which requires time and expert staff.

This updated review, involving around 9500 people, analysed data from an additional nine studies alongside the 18 included originally. Most of the studies were performed in low- or middle-income countries. The findings in the updated review are consistent with those reported previously.

The review found that for TB detection, Xpert MTB/RIF was accurate (it was sensitive (89%), detecting almost all cases; and specific (99%) that is, not registering positive in people who were actually negative).

For rifampicin resistance detection, Xpert MTB/RIF was accurate with sensitivity at 95% and specificity at 98%.

Xpert MTB/RIF appeared to have similar accuracy in people with and without HIV infection.

Applying the findings of the review to an imaginary group of 1000 people who go to their doctor with symptoms, but where only 100 of them (10%) actually have TB, Xpert MTB/RIF would diagnose 88 cases and miss 12, whereas smear microscopy would diagnose 65 cases and miss 35 cases.

Managing Editor of the Cochrane Infectious Diseases Group, Anne-Marie Stephani said: "Given the large number of studies that have assessed the accuracy of Xpert MTB/RIF, the WHO Global TB Programme commissioned a review to summarize the evidence. This updated review, like the original, shows that Xpert MTB/RIF is accurate for diagnosing TB and detecting rifampicin resistance, an indicator of multidrug-resistant TB. Xpert MTB/RIF may be useful in many countries, particularly in low- and middle-income countries where TB is prevalent, as it does not require advanced laboratory facilities or expert staff." She added, "The tests are expensive, so current research evaluating the use of Xpert MTB/RIF in TB programmes in high TB burden settings will help evaluate how this investment may help start treatment promptly and improve patient health."


'/>"/>
Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Cutting-edge approaches to ensuring biologic drug quality focus of forum on bioassays
2. Research: Chemoresponse assay helps boost ovarian cancer survival
3. Global Immunoassay Systems Market 2012 - 2016 Available by MarketResearchReports.Biz
4. Genomic assay as an alternative to animal testing
5. ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development for Cystic Fibrosis Patients
6. Harvard Medical School is Presenting “Neutrophil Chemotaxis Assay from One Drop of Blood” at Sample Prep East in Cambridge, MA, December 9-10, 2013
7. 17 Billion-Dollar Immunoassay Market Far From Mature, Says Kalorama Report
8. ATCC Examined the Importance of High-quality Controls in Assay Design and Development During the Association for Molecular Pathology (AMP) 2013 Annual Meeting
9. Vitamin C improves pulmonary function in newborns of pregnant smoking women
10. Pittsburgh Cardiologist Named Physician of the Year by Pulmonary Hypertension Association
11. A hands-on approach to treating patients with pulmonary disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of ... while encouraging readers to sign up as an organ donor for the 123,000 people ... , An organ donor can save up to 8 saves through organ donation and ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic Supplies - ... ... worldwide markets for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... forecasts are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: